Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Warfarin Use Can Increase Dementia Risk in AF Patients

By HospiMedica International staff writers
Posted on 19 May 2016
A new study shows that atrial fibrillation (AF) patients treated over a long period of time with Warfarin experience higher rates of dementia than their counterparts.

Researchers at Intermountain Medical Center (IMC; Salt Lake City, UT, USA) enrolled 10,537 patients with no prior history of dementia who were treated with warfarin for both AF and other, non-AF conditions (such as valvular heart disease and thromboembolism) on a long-term basis. More...
The researchers also examined other variables, such as age, hypertension, diabetes, hyperlipidemia, renal failure, smoking history, prior myocardial infarction (MI) or cerebral vascular accident, and heart failure. Participants were aged 18 years and older.

The results showed that during a follow-up of approximately seven years, dementia was more prevalent in the AF group (5.8%) than the non-AF group (1.6%). In both groups the risk of dementia increased as time in therapeutic range decreased, or became erratic; when warfarin levels were consistently too high or too low, dementia rates increased. Regardless of the adequacy of anticoagulation, the AF patients consistently experienced higher rates of all forms of dementia. The study was presented at the 37th annual scientific sessions of the Heart Rhythm Society, held during May 2016 in San Francisco (CA, USA).

“As physicians we have to understand that although we need to use anticoagulants for many reasons, including to prevent stroke in AF patients, at that same time there are risks that need to be considered, some of which we are only right now beginning to understand,” said lead author T. Jared Bunch, MD, director of heart rhythm research at IMC. “In this regard, only those that absolutely need blood thinners should be placed on them long-term. In people that are on warfarin in which the levels are erratic or difficult to control, switching to newer agents that are more predictable may lower risk.”

Warfarin decrease blood coagulation by inhibiting vitamin K epoxide reductase, an enzyme that recycles oxidized vitamin K to its reduced form after it has participated in the carboxylation of several blood coagulation proteins, mainly prothrombin and factor VII. It was initially introduced in 1948 as a pesticide against rats and mice and is still popular for this purpose. In the early 1950's warfarin was found to be effective and relatively safe for preventing thrombosis and embolism in many disorders. It is the most widely prescribed oral anticoagulant drug in North America.

Related Links:
Intermountain Medical Center

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Ureteral Dilatation Balloon
Dornier Equinox
Mobile X-Ray System
K4W
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.